Christian Schade - Jul 28, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Jul 28, 2022
Transactions value $
$0
Form type
4
Date filed
8/1/2022, 05:06 PM
Previous filing
Jun 7, 2022
Next filing
May 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +32.4K +14.28% $0.00 259K Jul 28, 2022 Direct F1
holding APRE Common Stock 1K Jul 28, 2022 By adult child F3
holding APRE Common Stock 1K Jul 28, 2022 By adult child F3
holding APRE Common Stock 1K Jul 28, 2022 By adult child F3
holding APRE Common Stock 1K Jul 28, 2022 By adult child F3
holding APRE Common Stock 1K Jul 28, 2022 By adult child F3
holding APRE Common Stock 1K Jul 28, 2022 By adult child F3
holding APRE Common Stock 5K Jul 28, 2022 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Option (right to Buy) Award $0 +47.6K $0.00 47.6K Jul 28, 2022 Common Stock 47.6K $1.09 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2 The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F3 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.